International Journal of Science and Technology (IJST)

Mitigating Nitrosamine Impurities in Pharmaceuticals: A Comprehensive Review

Nitrosamines, a class of substances recognized for their high mutagenic potency and classified as probable human carcinogens, have raised significant concerns within the pharmaceutical industry and regulatory authorities. These impurities may originate from reagents, catalysts, solvents, or raw materials employed during manufacturing processes, potentially contaminating drug substances and products. The presence of nitrosamine impurities in various medications, including valsartan, tetrazole-containing angiotensin II receptor blockers, ranitidine, metformin, and other pharmaceutical products, has led to numerous recalls and shortages. Beyond their carcinogenic risks, nitrosamines are implicated in the development of neurodegenerative conditions such as Alzheimer's and Parkinson's diseases, as well as type-2 diabetes. Consequently, effective mitigation strategies, including advanced analytical techniques such as LC-MS, GC-MS, CE-MS, and SFC, are essential for controlling or avoiding these impurities. Regulatory authorities, such as the USFDA, EMA, ICH, and WHO, play a critical role in addressing the risks associated with nitrosamine contamination. They should continue to provide guidance and periodic updates to drug manufacturers and applicants to ensure compliance and risk mitigation. Concurrently, manufacturers are encouraged to exercise diligence in preventing the occurrence of nitrosating agents and secondary amines during production processes. By implementing analytical methodologies that are both practical and compatible with industry requirements, and by resolving existing gaps in impurity detection, the pharmaceutical industry has the potential to significantly enhance the framework for nitrosamine risk evaluation, thereby reducing their adverse effects on public health.